Jennifer Sohn, MD
Endocrinology, Diabetes & Metabolism · Birmingham, ALNPI 1467665646
Payments from drug & device makers
What this record shows
Almost everything reported here is food and beverage — 99.1% of the total across 789 separate payments, which is the pattern of a clinician who attends manufacturer presentations rather than one with a consulting arrangement. It is spread thinly across 41 manufacturers, the largest accounting for just 12.3% — the pattern of someone who eats at a lot of different presentations.
Across 789 payments — averaging $17.62 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.
- Lilly USA, LLC$2K
- Novo Nordisk$2K
- Abbott$1K
- Bayer$1K
- Boehringer Ingelheim$1K
- AstraZeneca$939
- plus $6K from 35 others
What the payments were for
- Food & beverage$13,77699%
- Education$680%
- Gifts$590%
Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.
General payments by program year
Who reported the general payments
Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.
| Company | Payments | Total |
|---|---|---|
| Lilly USA, LLC | 110 | $1,710 |
| Novo Nordisk | 128 | $1,589 |
| Abbott | 77 | $1,494 |
| Bayer | 75 | $1,381 |
| Boehringer Ingelheim | 74 | $1,060 |
| AstraZeneca | 51 | $939 |
| Dexcom, Inc. | 39 | $819 |
| Xeris Pharmaceuticals, Inc. | 39 | $704 |
| Corcept Therapeutics | 30 | $690 |
| Amgen(2 entities) | 32 | $467 |
| Medtronic(2 entities) | 14 | $373 |
| Sanofi-aventis U.S. LLC | 19 | $317 |
| IBSA Pharma Inc. | 14 | $295 |
| AbbVie | 15 | $278 |
| BETA Bionics, Inc. | 5 | $241 |
| Tandem Diabetes Care, Inc. | 12 | $226 |
| Insulet Corporation | 10 | $212 |
| Kowa Pharmaceuticals America, Inc. | 2 | $130 |
| Novartis | 6 | $120 |
| Sequel Med Tech, LLC | 1 | $118 |
| Eisai Inc. | 1 | $100 |
| Radius Health, Inc. | 5 | $83 |
| Neurocrine Biosciences, Inc. | 3 | $72 |
| Mannkind Corporation | 1 | $59 |
| Johnson & Johnson | 4 | $59 |
| GSK | 3 | $52 |
| Endogastric Solutions, Inc | 1 | $30 |
| Amarin Pharma, Inc. | 2 | $30 |
| Amneal Pharmaceuticals LLC | 2 | $30 |
| Merck | 2 | $29 |
| Shire North American Group Inc | 2 | $26 |
| Ascendis Pharma Endocrinology Inc | 1 | $26 |
| Rhythm Pharmaceuticals, Inc. | 1 | $23 |
| Kyowa Kirin, Inc. | 1 | $21 |
| Tolmar, Inc. | 1 | $17 |
| Pfizer | 1 | $16 |
| Senseonics, Incorporated | 1 | $16 |
| Averitas Pharma Inc. | 1 | $16 |
| Lifescan, Inc. | 1 | $15 |
| Regeneron Healthcare Solutions, Inc. | 1 | $14 |
| Takeda Pharmaceuticals U.S.A., Inc. | 1 | $11 |
What the payments were tied to
Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.
- iLet Bionic Pancreas$440
- FreeStyle Libre$269
- Kerendia$122
- EVENITY$122
- TWIIST$118
- Livalo$116
- MINIMED 780G$106
How this compares
$13,904 in reported general payments places this provider in the 70th percentile of 79 endocrinology, diabetes & metabolism providers in Alabama.
See all endocrinology, diabetes & metabolism providers in Alabama →
Medicare billing
What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.
Most prescribed under Part D
| Drug | Claims | Cost to plans & patients |
|---|---|---|
| OzempicSemaglutide | 486 | $708,574 |
| MounjaroTirzepatide | 555 | $698,012 |
| JardianceEmpagliflozin | 278 | $307,050 |
| TrulicityDulaglutide | 183 | $237,663 |
| Toujeo SolostarInsulin Glargine,hum.Rec.Anlog | 157 | $111,104 |
| Tresiba Flextouch U-200Insulin Degludec | 101 | $108,832 |
| Tresiba Flextouch U-100Insulin Degludec | 118 | $91,747 |
| Humulin R U-500Insulin Regular, Human | 23 | $57,796 |
| FarxigaDapagliflozin Propanediol | 39 | $47,653 |
| Humalog Kwikpen U-200Insulin Lispro | 36 | $45,284 |
| GenotropinSomatropin | 21 | $37,811 |
| Fiasp FlextouchInsulin Aspart (Niacinamide) | 35 | $29,217 |
| Lantus SolostarInsulin Glargine,hum.Rec.Anlog | 210 | $29,167 |
| Omnipod 5 Dexg7g6 Pods (Gen 5)Insulin Pump Cart,auto,bt,g6/7 | 34 | $23,861 |
| HumalogInsulin Lispro | 57 | $22,560 |
Paid to pharmacies, not to this prescriber.
Companies that both paid and supply prescribed drugs
These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.
| Company | Paid to this provider | Part D cost of their drugs |
|---|---|---|
| Lilly USA, LLCMounjaro, Trulicity, Humalog | $1,710 | $958,235795 claims |
| Novo NordiskOzempic, Novolog | $1,589 | $724,977522 claims |
| Boehringer IngelheimJardiance, Tradjenta, Synjardy Xr | $1,060 | $340,273310 claims |
| AstraZenecaFarxiga | $939 | $47,65339 claims |
| PfizerGenotropin | $16 | $37,81121 claims |
| MerckJanuvia | $29 | $22,13621 claims |
| AbbVieSynthroid | $278 | $20,172221 claims |
| Johnson & JohnsonInvokana | $59 | $19,34911 claims |
| BayerKerendia | $1,381 | $14,78314 claims |
| Amneal Pharmaceuticals LLCLevothyroxine Sodium | $30 | $10,801602 claims |
| IBSA Pharma Inc.Tirosint | $295 | $10,63752 claims |
| Kowa Pharmaceuticals America, Inc.Livalo | $130 | $4,82313 claims |
Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 70th percentile of 79 endocrinology, diabetes & metabolism providers in Alabama.
Other endocrinology, diabetes & metabolism in Birmingham
- Ralph TeagueBirmingham$487K
- William GarveyBirmingham$421K
- Edison GoncalvesBirmingham$142K
- Fernando BrilBirmingham$74K
- Rodrigo ValderramaBirmingham$61K
- Janelle TownesBirmingham$56K
- Richard RosenthalBirmingham$24K
- Fernando OvalleBirmingham$15K
- Jorge PinoBirmingham$14K
- Malek KarassiBirmingham$14K
Where these figures come from
- Payments: CMS Open Payments, program years 2019–2025 (publication P06302026_06032026).
- Billing: Medicare Physician & Other Practitioners, data year 2024. Original Medicare Part B only.
- Identity: NPPES NPI Registry, July 2026.